← All trials
NCT04483739
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 25, 2020
- Primary completion
- Jul 31, 2025
- Completion date
- Dec 31, 2032
- First posted
- Jul 23, 2020
- Last posted
- Jan 5, 2021
- Enrollment
- 300
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- European Myeloma NetworkLead sponsor
- SanofiCollaborator
- AmgenCollaborator
- European Myeloma NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.